Nuevas terapias en cáncer colorrectal metastásico

Laburpena

Colorectal cancer (CRC) remains one of the most commonly diagnosed cancers, ranking fourth in terms of incidence and third in terms of mortality. More than 90% of cancer-associated deaths are due to the development of metastasis, a process favored by the acquisition of stem cell-like properties and cellular plasticity, including epithelial- mesenchymal transition. The metastatic cascade involves different steps involving growth factors, receptors, proteases, chemokines and cell adhesion molecules, such as cadherins and integrins that could be used as therapeutic targets. Currently, there are no effective treatments for the long-term survival of patients with CRC metastasis. This is due to the scarcity of therapeutic targets in metastasis and to the generation of resistance to both chemotherapy and current immunotherapy. For this reason, it is necessary to search for, identify and develop new targets that could be used in the treatment of CRC metastasis...